Study shows the beneficial effect of verapamil in children with newly-diagnosed type 1 diabetes

NewsGuard 100/100 Score

Published in JAMA, a University of Minnesota led study shows that verapamil, a drug commonly used to treat high blood pressure and heart conditions, can have a beneficial effect on the pancreas in children with newly-diagnosed type 1 diabetes (T1D).

Results of the CLVer clinical trial showed that oral verapamil taken once a day improved the pancreas' insulin secretion by 30% over the first year following diagnosis of T1D when compared with a control group that received a placebo.

The beneficial effect of verapamil observed in the trial is extremely exciting. Although we don't know whether the beneficial effect of verapamil on insulin secretion by the pancreas will be sustained once treatment was stopped at 12 months, we do know that better pancreas function in the first year is associated with better long-term outcomes in type 1 diabetes."

Antoinette Moran, MD, study's principal investigator and professor, University of Minnesota Medical School

The University of Minnesota was one of six pediatric diabetes centers in the U.S. that participated in the study. The trial included 88 children 8 to 17 years old who started the trial within 31 days of their T1D diagnosis. Participants were monitored for known side effects of verapamil, including effects on the heart, blood pressure and liver function. The study found that verapamil was well tolerated and very few of these side effects occurred.

In addition to evaluating verapamil, the trial also assessed whether an intensive glucose management approach that included use of an automated insulin delivery system to try to get glucose levels as close to normal as possible could have a beneficial effect on the pancreas' insulin secretion. As reported in a companion paper in JAMA, much better glucose levels were achieved with this approach compared with standard care that included use of continuous glucose monitoring; however, a benefit on the pancreas was not observed. Nevertheless, the glucose levels achieved could have long-term benefits in reducing complications of diabetes.

"The fact that verapamil is low cost and readily available, is taken orally once a day, and has a very favorable safety profile makes it a very appealing treatment for children and adults who are diagnosed to have type 1 diabetes" said Dr. Moran.

Funding was provided by JDRF, while Dexcom, Medtronic, and Tandem Diabetes Care provided devices and supplies used in the study.

Journal reference:

Forlenza, G.P., et al. (2023) Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes A Randomized Clinical Trial. JAMA.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research highlights positive impact of yoga and mediterranean diet on elderly health